Baiyunshan (600332.SH) subsidiary children's Xiaochaihu granules enter phase II clinical trial

Zhitongcaijing · 09/22/2025 10:57

Zhitong Finance App News, Baiyunshan (600332.SH) issued an announcement. Children's Xiaochaihu granules developed by the company's subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. (“Guanghua Pharmaceutical”) recently announced phase II clinical trial registration information on the China Drug Clinical Trial Registration and Information Disclosure Platform.

Specialized test title: Randomized, double-blind, parallel controlled design, multi-center phase II clinical study on the efficacy and safety of children with Xiaochaihu granules in treating children with gastrointestinal flu. Popular test title: Phase II clinical trial of Xiaochaihu granules for children to treat pediatric gastrointestinal flu offenders with Shaoyang.